natgillin/translations-raw huggingface dataset:
Kvinder i den fertile alder skal anvende sikker kontraception under behandling med Zonegran og i en måned efter seponering. (se pkt.
Women of childbearing potential have to use effective contraception during treatment with Zonegran and for one month after discontinuation (see section 4.6).
Kvinder i den fertile alder skal anvende sikker kontraception under behandling og indtil 3 måneder efter behandling
Women of childbearing potential must use effective contraception during and up to 3 months after treatment.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med Benepali og i 3 uger efter behandlingen for at undgå graviditet.
Women of childbearing potential should be advised to use appropriate contraception to avoid becoming pregnant during Benepali therapy and for three weeks after discontinuation of therapy.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med dette lægemiddel.
Women of childbearing potential should use adequate contraceptive measures during use of this medicine.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med Enbrel og i 3 uger efter behandlingen for at undgå graviditet.
Women of childbearing potential should be advised to use appropriate contraception to avoid becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med Jinarc.
Women of childbearing age must use reliable contraceptive measures during use of this medicine.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med Myocet og i op til 6 måneder efter behandlingsophør.
Women of childbearing potential should use an effective contraceptive during treatment with Myocet and up to 6 months following discontinuation of therapy.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med ofatumumab og i 12 måneder efter den sidste behandling med ofatumumab.
Women of childbearing potential have to use effective contraception during and for 12 months after the last ofatumumab treatment.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med pembrolizumab og i mindst 4 måneder efter den sidste pembrolizumabdosis.
Women of childbearing potential should use effective contraception during treatment with pembrolizumab and for at least 4 months after the last dose of pembrolizumab.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med Possia for at undgå graviditet.
Women of childbearing potential should use appropriate contraceptive measures to avoid pregnancy during Possia therapy.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med prucaloprid.
Women of childbearing potential should use effective contraception during treatment with prucalopride
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med prucaloprid.
Women of childbearing potential should use effective contraception during treatment with prucalopride.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med Rapamune og indtil 12 uger efter afslutning af behandlingen med Rapamune.
Effective contraception must be used during Rapamune therapy and for 12 weeks after Rapamune has been stopped.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med tedizolidphosphat.
Women of childbearing potential must use reliable contraception while taking tedizolid phosphate.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med tolvaptan.
Women of childbearing potential should use adequate contraceptive measures during tolvaptan use.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med Zonegran og i en måned efter seponeringen.
Women of childbearing potential have to use effective contraception during treatment with Zonegran, and for one month after discontinuation.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med zonisamid og i en måned efter seponeringen.
Women of childbearing potential must use adequate contraception during treatment with zonisamide, and for one month after discontinuation.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen og i 4 uger efter behandlingsophør af dabrafenib og 4 måneder efter den sidste dosis trametinib, når det gives i kombination med dabrafenib.
Women of childbearing potential must use effective methods of contraception during therapy and for 4 weeks following discontinuation of dabrafenib and 4 months following the last dose of trametinib when given in combination with dabrafenib.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen og i mindst 2 uger efter behandlingen og undgå at blive gravide under behandlingen med pazopanib.
Women of childbearing potential should be advised to use adequate contraception during the treatment and at least 2 weeks after treatment and avoid becoming pregnant while receiving treatment with pazopanib.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen og i mindst 3 måneder efter den sidste intravitreale injektion af aflibercept (se pkt.
Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last intravitreal injection of aflibercept (see section 4.6).
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen og i op til 3 måneder efter behandlingen.
Women of childbearing potential must use effective contraception during and up to 3 months after treatment.
Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen og indtil 6 måneder efter behandlingen med cladribine.
Women of childbearing potential must use effective contraception during treatment with cladribine and for 6 months after the last cladribine dose.
Kvinder i den fertile alder skal anvende sikker kontraception under og efter behandlingen.
Women of childbearing potential have to use effective contraception during and after treatment.
Kvinder i den fertile alder skal anvende sikker kontraception under ONIVYDE-behandlingen og i 1 måned derefter.
Women of childbearing potential should use effective contraception during ONIVYDE treatment and 1 month thereafter.
Kvinder i den fertile alder skal anvende sikker prævention under behandling med tafamidismeglumin og fortsætte med at bruge sikker prævention i 1 måned efter behandlingen med tafamidismeglumin er stoppet (se pkt.
Women of childbearing potential should use appropriate contraception when taking tafamidis meglumine and continue to use appropriate contraception for 1-month after stopping treatment with tafamidis meglumine (see section 4.6).
Kvinder i den fertile alder skal anvende sikker prævention under behandlingen og i 12 måneder efter behandlingen med MabThera på grund af den lange retentionstid for rituximab hos B-celle- depleterede patienter.
Due to the long retention time of rituximab in B cell depleted patients, women of childbearing potential must employ effective contraceptive methods during and for 12 months after treatment with MabThera.
Kvinder i den fertile alder skal anvende sikker prævention under behandlingen og i 12 måneder efter behandlingen med MabThera på grund af den lange retentionstid for rituximab hos B-celle- depleterede patienter.
Due to the long retention time of rituximab in B cell depleted patients, women of childbearing potential should use effective contraceptive methods during and for 12 months following treatment with MabThera.
Kvinder i den fertile alder skal anvende sikker prævention under behandlingen og i mindst 3 måneder efter den sidste injektion af Eylea.
Women of childbearing potential have to use effective contraception during treatment and for at least three further months after the last injection of Eylea.
Kvinder i den fertile alder skal anvende svangerskabsforebyggende midler under behandling med rufinamid.
Women of childbearing potential must use contraceptive measures during treatment with rufinamide.
Kvinder i den fertile alder skal anvende yderst sikker kontraception (fx orale, injicerede eller implanterede ikke-østrogenholdige hormonale præventionsmetoder, progesteron-baserede kontraceptiva, hysterektomi, aflukning af æggeledere, fuldstændig afholdenhed, barriereprævention, intrauterin prævention [IUD] og/eller kvindelig/mandlig sterilisation) under behandlingen med everolimus og i op til 8 uger efter endt behandling.
Women of childbearing potential must use a highly effective method of contraception (e.g. oral, injected, or implanted non-oestrogen-containing hormonal method of birth control, progesterone-based contraceptives, hysterectomy, tubal ligation, complete abstinence, barrier methods, intrauterine device [IUD], and/or female/male sterilisation) while receiving everolimus, and for up to 8 weeks after ending treatment.
Kvinder i den fertile alder skal anvende yderst sikker kontraception under behandling med Tasigna og i to uger efter endt behandling.
Women of childbearing potential have to use highly effective contraception during treatment with Tasigna and for up to two weeks after ending treatment.
Kvinder i den fertile alder skal benytte sikker kontraception i 4 uger før behandlingen, under behandlingen samt 4 uger efter thalidomidbehandlingen, også ved pausering af behandlingen, medmindre patienten forpligter sig til fuldstændig og vedvarende seksuel afholdenhed, som bekræftes månedligt.
Women of childbearing potential must use one effective method of contraception for 4 weeks before therapy, during therapy, and during 4 weeks after thalidomide therapy and even in case of dose interruption unless the patient commits to absolute and continuous abstinence confirmed on a monthly basis.
Kvinder i den fertile alder skal bruge effektiv prævention under behandling og i mindst 6 måneder efter behandlingen.
Women of childbearing potential have to use effective contraception during treatment and for at least 6 months after treatment.
Kvinder i den fertile alder skal bruge sikker antikonception under behandlingen og i fem måneder efter behandlingen.
Women of childbearing potential have to use effective contraception during treatment and up to 5 months after treatment.
Kvinder i den fertile alder skal bruge sikker prævention, mens de er i behandling med Perjeta og i 6 måneder efter den sidste dosis.
Women of childbearing potential should use effective contraception while receiving Perjeta and for 6 months following the last dose of Perjeta.
Kvinder i den fertile alder skal informeres om at anvende sikker kontraception under behandlingen og i 4 måneder efter seponering af trametinib.
Advise female patients of reproductive potential to use highly effective contraception during treatment with trametinib and for 4 months after treatment.
Kvinder i den fertile alder skal informeres om, at regorafenib kan medføre medfødte misdannelser.
Women of childbearing potential must be informed that regorafenib may cause foetal harm.
Kvinder i den fertile alder skal opfordres til at undgå at blive gravide, mens de får cabozantinib.
Women of childbearing potential must be advised to avoid pregnancy while on cabozantinib.
Kvinder i den fertile alder skal rådes til at anvende sikker kontraception og undgå graviditet under behandlingen med Bosulif.
Women of childbearing potential should be advised to use effective contraception and avoid becoming pregnant while receiving Bosulif.
Kvinder i den fertile alder skal rådes til at anvende sikker prævention og undgå graviditet under behandlingen med SUTENT.
Women of childbearing potential should be advised to use effective contraception and avoid becoming pregnant while receiving treatment with SUTENT.
Kvinder i den fertile alder skal rådes til ikke at blive gravide, så længe de behandles med capecitabin.
Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with capecitabine.
Kvinder i den fertile alder skal tilrådes at undgå at blive gravide, mens de får ZALTRAP, og skal informeres om de potentielle risici for fosteret.
Women of childbearing potential should be advised to avoid becoming pregnant while on ZALTRAP, and should be informed of the potential hazard to the foetus.
Kvinder i den fertile alder skal tilrådes at undgå at blive gravide.
Women of child- bearing potential should be advised to avoid becoming pregnant.
Kvinder i den fertile alder skal tilrådes at undgå graviditet, mens de er i behandling med dette lægemiddel.
Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with this medicinal product.
Kvinder i den fertile alder skal tilrådes at undgå graviditet, mens de får cabozantinib.
Women of childbearing potential must be advised to avoid pregnancy while on cabozantinib.
Kvinder i den fertile alder skal undgå at blive gravide og anvende meget sikker kontraception, mens de er i behandling med lenvatinib og mindst en måned efter behandlingsophør.
Women of childbearing potential should avoid becoming pregnant and use highly effective contraception while on treatment with lenvatinib and for at least one month after finishing treatment.
Kvinder i den fertile alder skal undgå at blive gravide under behandling med edoxaban.
Women of childbearing potential should avoid becoming pregnant during treatment with edoxaban.
Kvinder i den fertile alder, som behandles med Iclusig, bør undgå at blive gravide.
Women of childbearing age being treated with Iclusig should avoid becoming pregnant.
Kvinder i den fertile alder, som behandles med Iclusig, skal rådes til at undgå graviditet, og mænd, der behandles med Iclusig, skal frarådes at gøre kvinder gravide.
Women of childbearing age being treated with Iclusig should be advised not to become pregnant and men being treated with Iclusig should be advised not to father a child during treatment.
Kvinder i den fertile alder/antikonception hos kvinder
Women of childbearing potential/contraception in females
Kvinder i den fertile alder/antikonception hos mænd og kvinder.
Women of childbearing potential/Contraception in males and females
Kvinder i den fertile alder/Antikonception til mænd og kvinder
Women of childbearing potential/Contraception in males and females
Kvinder i den fertile alder/Kontraception hos mænd og kvinder
Woman of childbearing potential/Contraception in the males and females
Kvinder i den fertile alder/Kontraception til kvinder
Women of childbearing potential / Contraception in females
Kvinder i den fertile alder/kontraception til mænd og kvinder
Women of child-bearing potential/contraception in males and females
Kvinder i den fertile alder/prævention
Women of childbearing potential / Contraception
Kvinder i den fertile alder/prævention hos mænd og kvinder
Women of childbearing potential / Contraception in males and females
Kvinder i den fertile alder/Prævention hos mænd og kvinder
Women of childbearing potential/Contraception in males and females
Kvinder i den fertile alder:
For women with child-bearing potential:
Kvinder i den fertile kvinder skal anvende en sikker kontraceptionsmetode.
Women of childbearing potential should use effective method of contraception.
Kvinder i den fødedygtige alder bør anvende pålidelige svangerskabsforebyggelsesmetoder for at undgå graviditet, mens de behandles med Depocyte.
Women of childbearing potential should use a reliable contraceptive method to avoid pregnancy whilst being treated with DepoCyte.
Kvinder i den fødedygtige alder bør undgå kontakt med produktet eller anvende beskyttelseshandsker, når produktet gives.
Women of child-bearing age should avoid contact with, or wear disposable gloves, when administering the product.
Kvinder i den fødedygtige alder må ikke tage Leflunomid Winthrop, medmindre de anvender sikker prævention.
Women of childbearing potential must not take Leflunomide Winthrop without using reliable contraceptive measures.
Kvinder i den fødedygtige alder må kun tage AUBAGIO, hvis de bruger en effektiv præventionsmetode.
Women of childbearing potential must not take AUBAGIO without using reliable contraceptive measures.
Kvinder i den fødedygtige alder skal anvende effektiv antikonception under behandling med Vectibix og i 2 måneder efter den sidste dosis.
If you are a woman of child bearing potential, you should use effective methods of contraception during treatment with Vectibix and for 2 months after the last dose.
Kvinder i den fødedygtige alder skal anvende effektiv antikonception under behandlingen med Inovelon.
Women of childbearing potential must use contraceptive measures during treatment with Inovelon.
Kvinder i den fødedygtige alder skal anvende en effektiv metode til fødselskontrol, mens de anvender Panretin og i 1 måned efter afslutningen af behandlingen.
Women of child-bearing age must use an effective method of birth control while using Panretin, and for one month after finishing treatment.
Kvinder i den fødedygtige alder skal anvende en pålidelig form for kontraception under behandling med Panretin gel (se afsnit 4.6) og indtil 1 måned efter behandlingsophør.
Women of child-bearing potential must use a reliable form of contraception during treatment with Panretin gel (see section 4.6) and until one month after cessation of treatment.
Kvinder i den fødedygtige alder skal anvende sikker kontraception;
That women of childbearing potential must use reliable contraception;
Kvinder i den fødedygtige alder skal anvende sikker prævention under behandlingen med Cimzia og i mindst 5 måneder efter den sidste behandling med Cimzia.
Women of childbearing potential must use adequate contraception while using Cimzia and for at least 5 months after the last Cimzia treatment.
Kvinder i den fødedygtige alder skal anvende sikker prævention under behandlingen med Simbrinza.
Women who may become pregnant are advised to use effective contraception during SIMBRINZA treatment.
Kvinder i den fødedygtige alder skal anvende sikre præventionsmetoder under og i 4 måneder efter hvert behandlingsforløb med LEMTRADA.
Women who are able to conceive should use effective contraceptive methods during each treatment course with LEMTRADA and for 4 months after each course of treatment.
Kvinder i den fødedygtige alder skal anvende svangerskabsforebyggende midler under behandlingen med rufinamid.
Women of childbearing potential must use contraceptive measures during treatment with rufinamide.
Kvinder i den fødedygtige alder skal benytte passende antikonception.
Women of child-bearing potential have to take appropriate contraceptive measures.
Kvinder i den fødedygtige alder skal bruge en effektiv præventionsmetode for at undgå, at blive gravid under behandlingen.
Women of child-bearing potential should use effective contraception to avoid becoming pregnant while on treatment.
Kvinder i den fødedygtige alder skal bruge sikker antikonception under behandling med SCENESSE og i tre måneder efterfølgende.
Women of childbearing potential should, use effective contraception during treatment with SCENESSE and for a period of three months thereafter.
Kvinder i den fødedygtige alder skal bruge sikker prævention, så længe de er i behandling med Vyndaqel, og de skal fortsætte med den svangerskabsforebyggende behandling i 1 måned efter behanding med Vyndaqel er stoppet.
Women that can become pregnant should use birth control while taking Vyndaqel and should continue using birth control for one month after stopping treatment with Vyndaqel.
Kvinder i den fødedygtige alder skal bruge tilstrækkelig antikonception og straks informere lægen, hvis de har mistanke om at være gravide
Women of childbearing potential should have adequate birth control and should tell their doctors immediately if they suspect they may be pregnant;
Kvinder i den fødedygtige alder skal bruge yderst effektiv prævention under behandlingen og i to uger efter endt behandling.
Women who might get pregnant are advised to use highly effective contraception during treatment and for up to two weeks after ending treatment.
Kvinder i den fødedygtige alder skal oplyse deres læge om muligheden for graviditet før behandling med dette lægemiddel.
Women of child-bearing potential should inform their surgeon of the possibility of pregnancy before they are administered this medicine.
Kvinder i den fødedygtige alder skal tage de nødvendige forholdsregler for at undgå graviditet i 1 måned efter vaccination, eller efter lægens anvisning.
Females of child-bearing age should take the necessary precautions to avoid pregnancy for 1 month, or according to doctor’s recommendation, after they have been given the vaccine.
Kvinder i den fødedygtige alder skal tage nødvendige forholdsregler for at undgå graviditet i 1 måned efter vaccination.
Women of child-bearing potential should take the necessary precautions to avoid pregnancy for 1 month following vaccination.
Kvinder i den fødedygtige alder skal undgå at blive gravide under behandling med vareniclin.
Women of child bearing potential should avoid becoming pregnant during treatment with varenicline.
Kvinder i den fødedygtige alder som ikke anvender prævention (se pkt.
Women of childbearing potential not using contraceptive measures (see section 4.6).
Kvinder i den fødedygtige alder, skal bruge sikker prævention, under RoActemra-behandling og i op til 3 måneder efter behandlingen.
Women of childbearing potential must use effective contraception during and up to 3 months after treatment.
Kvinder i den fødedygtige alder/antikonception til mænd og kvinder
Women of childbearing potential/contraception in females
Kvinder i den fødedygtige alder/kontraception hos mænd og kvinder
Women of childbearing potential/Contraception in males and females
Kvinder i den fødedygtige alder/prævention
Women of child-bearing potential/contraception
Kvinder i den fødedygtige alder:
Women of child-bearing age
Kvinder i den fødedygtige alder:
Women of childbearing age
Kvinder i fertil alder
Women of child-bearing potential
Kvinder i fertil alder/kontraception hos kvinder
Women of childbearing potential/ Contraception in females
Kvinder i fødedygtig alder skal bruge sikker antikonception, mens de får PhotoBarr og op til 90 dage efter at have fået PhotoBarr..
Women of childbearing age should take adequate contraceptive precautions whilst and up to 90 days after receiving PhotoBarr.
Kvinder kan behøve en højere dosis end mænd.
Women may require higher doses than men.
Kvinder kan opleve, at det tager længere tid at blive gravid, efter at de stopper med at anvende EVRA.
Women may experience a delay in conception following discontinuation of EVRA.
Kvinder med anovulation (inkl. polycystisk ovariesyndrom)
Women with anovulation (including polycystic ovarian syndrome)
Kvinder med brystkræft, som fik Prolia, fik også øget knogletæthed i den nedre del af rygsøjlen efter ét år.
Women with breast cancer who took Prolia also had higher bone density in the lower spine after one year.
Kvinder med en kropsvægt på under 50 kg eller over 90 kg
Women weighing less than 50 kg or more than 90 kg
Kvinder med hiv må ikke amme, da spædbørn kan blive smittet med hiv gennem modermælken.
Women with HIV should not breast-feed their infants because babies can be infected with HIV through their breast milk.
Kvinder med hypertriglyceridæmi eller familiær disposition herfor, kan have en øget risiko for pancreatitis, når de anvender p-piller.
Women with hypertriglyceridaemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.
Kvinder med hypertriglyceridæmi eller som har det i familiens sygehistorie, kan være udsat for øget risiko for pankreatitis ved anvendelse af kombinerede hormonale præventionsmidler.
Women with hypertriglyceridaemia, or a family history thereof, may be at an increased risk of pancreatitis when using combined hormonal contraceptives.
Kvinder må ikke amme under behandlingen med Lynparza og mindst én måned efter behandlingen.
Women must not breastfeed during treatment with Lynparza and for at least one month after treatment.
Kvinder må ikke blive gravide, mens de tager Eviplera.
Women must not get pregnant while taking Eviplera.
Kvinder må ikke blive gravide, mens de tager Stribild.
Women must not get pregnant while taking Stribild.